Observational studyCritical care medicine2024
Prevalence and Survival of Prolonged Venovenous Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: An Analysis of the Extracorporeal Life Support Organization Registry.
Observational study in Critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Novel use of negative pressure ventilation for weaning of venovenous extracorporeal membrane oxygenation.Perfusion · 2026Article
- The six phases of prolonged veno-venous extracorporeal membrane oxygenator support: a conceptual framework.Critical care (London, England) · 2026Review
- Clinical outcomes of VA-ECMO in children with fulminant myocarditis: a single-centre case series.BMC pediatrics · 2026Article
- Queensland adult ECMO retrieval service: A description of the service and analysis of outcomes.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2026Article
- Pathogenesis of MRSA-influenza co-infection: implications for ECMO therapeutic strategies - a mini-review.Frontiers in immunology · 2026Review
- Perioperative Veno-Venous Extracorporeal Membrane Oxygenation in Non-Elective Thoracic Surgery: A Propensity-Matched Bicentric Comparison With Medical Indication.Interdisciplinary cardiovascular and thoracic surgery · 2025Observational
- Prognosis After Seven Days of Veno-Venous Extracorporeal Membrane Oxygenation Support.Artificial organs · 2025Article
- Review
- Outcomes of Venovenous Extracorporeal Membrane Oxygenation for Pneumocystis jirovecii Pneumonia: A Multicenter Retrospective Case Series.Critical care explorations · 2025Article
- Outcomes and Prognosis of COVID-19-Induced Adult Respiratory Distress Syndrome Patients Treated with Prolonged Veno-Venous Extracorporeal Membrane Oxygenation: A Retrospective Multicenter Study.Journal of clinical medicine · 2024Article
- Improving oxygenation in severe ARDS treated with VV-ECMO: comparative efficacy of moderate hypothermia and landiolol in a swine ARDS model.Intensive care medicine experimental · 2024Article
- Venovenous Extracorporeal Membrane Oxygenation: In for a Penny, In for a Pound.Critical care medicine · 2024Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine trends in utilization and outcomes among patients with the acute respiratory distress syndrome (ARDS) requiring prolonged venovenous extracorporeal membrane oxygenation (VV ECMO) support.
designRetrospective observational cohort study.
settingAdult patients in the Extracorporeal Life Support Organization registry. PATIENTS: Thirteen thousand six hundred eighty-one patients that required ECMO for the support of ARDS between January 2012 and December 2022.
interventionsNone. MEASUREMENTS AND MAIN
resultsMortality while supported with VV ECMO and survival to hospital discharge based on ECMO duration were examined utilizing multivariable logistic regression. Among the 13,681 patients supported with VV ECMO, 4,040 (29.5%) were supported for greater than or equal to 21 days and 975 (7.1%) for greater than or equal to 50 days. Patients supported with prolonged VV ECMO were less likely to be discharged alive from the hospital compared with those with short duration of support (46.5% vs. 59.7%; p < 0.001). However, among patients supported with VV ECMO greater than or equal to 21 days, duration of extracorporeal life support was not significantly associated with mortality (odds ratio [OR], 0.99; 95% CI, 0.98-1.01; p = 0.87 and adjusted OR, 0.99; 95% CI, 0.97-1.02; p = 0.48). Even in those supported with VV ECMO for at least 120 days (n = 113), 52 (46.0%) of these patients were ultimately discharged alive from the hospital.
conclusionsProlonged VV ECMO support of ARDS has increased and accounts for a substantial portion of cases. Among patients that survive for greater than or equal to 21 days while receiving VV ECMO support, duration is not predictive of survival to hospital discharge and clinical recovery may occur even after very prolonged VV ECMO support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.